TVTX · XBRL financial data

Travere Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (TVTX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	198	227	212	145	233	491
Cost of goods and services sold	6	7	8	11	8	10
Research and development	—	—	8	—	—	—
Selling, general and administrative	136	150	220	266	264	337
Operating income (loss)	(176)	(162)	(267)	(388)	(324)	(63)
Interest income	5	2	6	22	18	13
Interest expense	19	20	11	11	11	11
Other income (expense)	1	0	1	2	(3)	12
Income tax expense (benefit)	(19)	0	0	0	0	1
Net income (loss)	(169)	(180)	(278)	(111)	(322)	(26)
Earnings per share, basic USD per share	(3.56)	(3.01)	(4.37)	(1.50)	(4.08)	(0.29)
Earnings per share, diluted USD per share	(3.56)	(3.01)	(4.37)	(1.50)	(4.08)	(0.29)
Weighted average shares, basic millions of shares	48	60	64	74	79	89
Weighted average shares, diluted millions of shares	48	60	64	74	79	89

Fiscal years (TVTX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	85	166	62	58	59	93
Marketable securities	272	262	286	249	—	145
Marketable securities, non-current	5	125	103	260	—	84
Accounts receivable	16	16	17	21	27	80
Inventory	8	7	7	9	6	36
Prepaid and other current assets	8	6	13	19	13	29
Total current assets	410	583	486	617	417	438
Property and equipment, net	9	11	9	7	5	4
Right-of-use asset	26	23	21	18	14	11
Goodwill	1	1	1	1	1	—
Total assets	607	777	673	789	594	605
Accounts payable	12	15	17	42	24	25
Accrued liabilities	57	75	96	119	86	126
Total current liabilities	93	124	142	178	201	160
Lease liability, non-current	28	31	28	23	17	11
Total liabilities	396	475	630	588	535	490
Accumulated deficit	(586)	(766)	(1,014)	(1,126)	(1,447)	(1,473)
Total stockholders' equity	211	302	43	201	59	115
Total liabilities and equity	607	777	673	789	594	605
Common shares outstanding (cover page) millions of shares	60	63	65	76	89	92

Fiscal years (TVTX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(169)	(180)	(278)	(111)	(322)	(26)
Stock-based compensation	24	31	39	44	37	45
Depreciation and amortization	25	27	33	39	44	61
Net cash from operating activities	(43)	(15)	(186)	(280)	(237)	38
Purchases of property and equipment	7	5	0	1	—	—
Net cash from investing activities	(61)	(138)	(33)	56	99	28
Proceeds from issuing common stock	—	189	0	191	135	0
Repayments of long-term debt	0	—	—	—	—	—
Net cash from financing activities	128	232	118	219	139	(33)
Net change in cash	22	81	(104)	(4)	0	35

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Travere Therapeutics	124	225	98*	96.0M	—	Q3 FY26 10-QSep 30, 2026
Ani Pharmaceuticals	360	266	57*	not reported	—	Q2 FY26 10-QJun 30, 2026
Celldex Therapeutics	47	0	(57)*	78.5M	12.5 quarters	Q2 FY26 10-QJun 30, 2026
Innoviva	570	120	52*	72.2M	—	Q2 FY26 10-QJun 30, 2026
Adaptive Biotechnologies	170	72	(6.4)*	159.6M	53.8 quarters	Q2 FY26 10-QJun 30, 2026
Arrowhead Pharmaceuticals	55	75	(177)*	141.3M	9.0 quarters	Q3 FY26 10-QJun 30, 2026
Mannkind	53	109	(18)*	321.5M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Schrodinger	288	59	(34)*	not reported	12.1 quarters	Q2 FY26 10-QJun 30, 2026
Spyre Therapeutics	83	not reported	(77)*	95.0M	15.7 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.